These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 6348940

  • 21. Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.
    Cederberg C, Lind T, Röhss K, Olbe L.
    Digestion; 1992; 53(3-4):171-8. PubMed ID: 1291405
    [Abstract] [Full Text] [Related]

  • 22. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs.
    De Graef J, Woussen-Colle MC.
    Gastroenterology; 1986 Aug; 91(2):333-7. PubMed ID: 2873074
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of gastric acid secretion by omeprazole in the dog and rat.
    Larsson H, Carlsson E, Junggren U, Olbe L, Sjöstrand SE, Skånberg I, Sundell G.
    Gastroenterology; 1983 Oct; 85(4):900-7. PubMed ID: 6884713
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of esaprazole activity on basal gastric secretion and on pentagastrin-stimulated secretion in healthy volunteers.
    Erembourg L, Reggiani P, Tosi GP, Ferla G, Beinat L.
    Int J Clin Pharmacol Res; 1987 Oct; 7(2):95-100. PubMed ID: 3583500
    [Abstract] [Full Text] [Related]

  • 25. Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man.
    Kittang E, Aadland E, Schjønsby H.
    Gut; 1985 Jun; 26(6):594-8. PubMed ID: 3924748
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
    Pisegna JR, Martin P, McKeand W, Ohning G, Walsh JH, Paul J.
    Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
    [Abstract] [Full Text] [Related]

  • 27. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
    Simon B, Müller P, Hartmann M, Bliesath H, Lühmann R, Huber R, Bohnenkamp W, Wurst W.
    Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
    [Abstract] [Full Text] [Related]

  • 28. The effect of omeprazole on insulin induced gastric secretion in man.
    Utley RJ, Wright R, Beastall GH, Carter DC.
    Scott Med J; 1985 Apr; 30(2):96-100. PubMed ID: 3892679
    [Abstract] [Full Text] [Related]

  • 29. Omeprazole inhibition of nocturnal gastric secretion in patients with duodenal ulcer.
    Hetzel DJ, Shearman DJ.
    Br J Clin Pharmacol; 1984 Oct; 18(4):587-90. PubMed ID: 6487498
    [Abstract] [Full Text] [Related]

  • 30. Effect of omeprazole on gastric acid secretion and plasma gastrin.
    Olbe L, Cederberg C, Lind T, Olausson M.
    J Gastroenterol Hepatol; 1989 Oct; 4 Suppl 2():19-25. PubMed ID: 2491358
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Omeprazole and inhibition of gastric acid secretion].
    Rossi G.
    Recenti Prog Med; 1984 Apr; 75(4):419-21. PubMed ID: 6729204
    [No Abstract] [Full Text] [Related]

  • 34. Effect of intermittent weekend therapy with omeprazole on basal and bombesin- and pentagastrin-stimulated gastric acid and serum gastrin.
    Crobach LF, Jansen JB, Lamers CB.
    Scand J Gastroenterol; 1988 May; 23(4):407-12. PubMed ID: 3381063
    [Abstract] [Full Text] [Related]

  • 35. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 36. Effect of inhibition of pentagastrin-stimulated acid secretion on gastric mucosal gland luminal pressure.
    Synnerstad I, Persson AE, Holm L.
    Acta Physiol Scand; 1997 May; 160(1):103-11. PubMed ID: 9179318
    [Abstract] [Full Text] [Related]

  • 37. Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. A Scandinavian Multicentre Study.
    Scand J Gastroenterol; 1984 Oct; 19(7):882-4. PubMed ID: 6397846
    [Abstract] [Full Text] [Related]

  • 38. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.
    Prichard PJ, Yeomans ND, Mihaly GW, Jones DB, Buckle PJ, Smallwood RA, Louis WJ.
    Gastroenterology; 1985 Jan; 88(1 Pt 1):64-9. PubMed ID: 3880557
    [Abstract] [Full Text] [Related]

  • 39. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.
    Jansen JB, Lundborg P, Baak LC, Greve J, Ohman M, Stöver C, Röhss K, Lamers CB.
    Gut; 1988 Jan; 29(1):75-80. PubMed ID: 3343017
    [Abstract] [Full Text] [Related]

  • 40. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
    Periclou AP, Goldwater R, Lee SM, Park DW, Kim DY, Cho KD, Boileau F, Jung WT.
    Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.